Table 2

Baseline Clinical Data and 11C-PiB PET/CT Results of Each Study Participant

Patient #Age, yrsSexBiopsyPiB PET/CTECG Low VoltageChemotherapy Before the EnrollmentAmyloid In Other OrgansΔFLC (Before Chemotherapy)ΔFLC (After Chemotherapy)
ImmunohistochemistryUptakeMaximal LV Myocardium-Blood Cavity RatioMean LV Myocardium-Blood Cavity Ratio
159FλYes3.862.27YesNo
251FλYes13.944.94YesNo
364MλYes19.928.92YesNo
475FλYes18.0310.70YesNoKidney
560FκYes13.517.60YesNoKidney
679FκYes3.631.69YesNo
764MλYes4.262.28YesNo
867MλYes15.899.41YesNo
972MκYes7.273.73YesNo
1061MλYes2.290.99NoMD#3→Auto-PBSCT117 (27/144)26 (17/43)
1153MλYes3.811.08YesMD#1207 (28/235)38 (3/41)
1269FλYes2.391.17NoMD#1144 (16/160)70 (32/102)
1351FκYes2.051.19YesTD#1350 (606/256)48 (50/2)
1445FκNo1.690.95YesNoKidney
1562MλNo1.680.64YesTD #635/1,151 (1,116)
1679MNonamyloidNo0.920.87YesNo
1767MNonamyloidNo1.031.00NoNo
1876FNonamyloidNo0.970.96NoNo
1950FNonamyloidNo1.230.95YesNoKidney, liver
2077FNonamyloidNo0.890.76NoNo
2176FNonamyloidNo0.760.66YesNo
2273MNonamyloidNo1.110.98YesNo

Individual clinical and 11C-PiB PET/CT results of the study participants are listed. All patients were diagnosed with cardiac amyloidosis by positive Congo red and amyloid P immunohistochemical staining on endomyocardial biopsy. The immunostaining of the endomyocardial biopsy samples were also matched with the serum free light chain assay results. A cutoff value for positive versus negative 11C-PiB PET/CT was defined as maximal myocardium-to-blood cavity ratio ≥2.0 on the basis of results of control subjects in Table 1. The difference between the involved and uninvolved free light chain levels is shown in the ΔFLC column with κ and λ levels in the parenthesis, respectively. #n indicates number of cycles of chemotherapy.

ECG = electrocardiogram; FLC = free light chain; MD = melphalan + dexamethasone; PBSCT = peripheral blood stem cell transplantation; TD = thalidomide + dexamethasone; other abbreviations as in Table 1.